vibro-tactile stimulation (VTS) for Hoarseness

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Hoarseness+7 More
vibro-tactile stimulation (VTS) - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether vibro-tactile stimulation can help improve the speech of people with laryngeal dystonia (a movement disorder that affects the muscles of the larynx).

Eligible Conditions
  • Hoarseness
  • Dysphonia
  • Laryngeal Dystonia
  • Spastic Dysphonia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 24 months

24 months
Change in perceived speech effort (PSE)
Change in smoothed cepstral peak prominence (CPPS)
Change in speech quality vector (SQV) (%)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

4 Treatment Groups

Low dose / speech activated VTS
1 of 4
Low dose / continuous VTS
1 of 4
High dose / speech activated VTS
1 of 4
High dose / continuous VTS
1 of 4

Experimental Treatment

60 Total Participants · 4 Treatment Groups

Primary Treatment: vibro-tactile stimulation (VTS) · No Placebo Group · Phase 2

Low dose / speech activated VTS
Device
Experimental Group · 1 Intervention: vibro-tactile stimulation (VTS) · Intervention Types: Device
Low dose / continuous VTS
Device
Experimental Group · 1 Intervention: vibro-tactile stimulation (VTS) · Intervention Types: Device
High dose / speech activated VTS
Device
Experimental Group · 1 Intervention: vibro-tactile stimulation (VTS) · Intervention Types: Device
High dose / continuous VTS
Device
Experimental Group · 1 Intervention: vibro-tactile stimulation (VTS) · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,243 Previous Clinical Trials
1,481,443 Total Patients Enrolled
3 Trials studying Hoarseness
142 Patients Enrolled for Hoarseness

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are at least 18 years old.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: November 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.